Four sections were categorized regarding pregnancy outcomes: pre-clinical/animal studies, human female fertility, pregnancy-related outcomes and congenital malformations in the human fetus. Three sections were categorized regarding lactation outcomes: pre-clinical/animal studies, excretion in human breast milk and absorption in children through breastfeeding. The clinical applicability of each category was scored by specified criteria, based on scientific literature, and further as defined by the authors. Results: For the 16 included biologics, post-authorization data were delivered only for adalimumab, certolizumab pegol, etanercept and infliximab. For the 12 remaining biologics limited data on pregnancy and lactation during the post-marketing period of 2-21 years were available.
| INTRODUCTION
Biologics are widely used in rheumatologic and gastroenterological inflammatory autoimmune diseases. Their use in women of childbearing potential is expected and subsequently detailed information on the impact of these drugs on reproduction is therefore of utmost importance. 1 In Europe, the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and the European Medicines Agency (EMA) established rules to report on the reproductive safety of (approved) drugs. These rules include the ICH-S5 guideline (1993, discusses detection of toxicity to reproduction mostly in preclinical/animal studies), the ICH-S6 guideline (2011, recommends a basic framework for the preclinical safety evaluation of biotechnology-derived pharmaceuticals), the EMA "Guideline on the exposure to medicinal products during pregnancy: Need for post-authorisation data" (2006) and the "Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling" (2009). [2] [3] [4] [5] [6] [7] [8] [9] [10] All these guidelines provide a minimum framework for the pharmaceutical industry to perform pregnancy-and fertility-related studies before and after registration.
Our first objective was to investigate the data on pregnancy and lactation made publicly available by pharmaceutical companies at the time and after marketing authorization in Europe of biologics for the indications of rheumatologic and inflammatory bowel diseases. Secondary objectives included the assessment of the clinical relevance of the provided data and comparison of the initial provided data to postauthorization data. It should be noted that this study is not a review of the scientific literature from published papers.
| MATERIALS AND METHODS

| Inclusion criteria
The inclusion criteria for the investigated biologics were:
• Approved by EMA from 1 January 1999 to 31 December 2018.
• Indicated for rheumatologic or inflammatory bowel diseases.
Initial available data at the time of authorization for the selected biologicals were investigated. The data were extracted by one investigator (N.G.) from the oldest publicly accessible "Initial scientific discussions" in the European Public Assessment Reports (EPARs) for each biological from the EMA official website. 11 The extracted information used in these comparisons is from the sections in the initial dossiers discussed in the EPARs called "Reproduction Toxicity", "Toxico-pharmacological aspects" and "Toxicokinetics". [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] The data added during the post marketing period were extracted from the latest versions (to 7 May 2019) of the Summary of Product Characteristics (SmPCs). The additional post-marketing data were considered as the data related to pregnancy and/or lactation not mentioned in the initial dossiers but mentioned in the latest version of SmPCs in the sections "4.6 Fertility, pregnancy and lactation" and "5.3
Preclinical safety data". [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] 
| Pregnancy information sections
The provided information was categorized as follows: (a) preclinical/animal studies, (b) human female fertility, (c) pregnancy-related outcomes, (d) congenital malformations in the human fetus and (e) recommendations regarding continuation and/or discontinuation during pregnancy Table 1 .
The data per category were considered adequate when they fulfilled the following criteria (shown in green in Tables 2 and 3): 1. Pre-clinical/animal studies: When the requirements of the ICH-S5 and ICH-S6 guidelines are fulfilled during the pre-marketing period. 6, 8 2. Human female fertility: When data is provided on evaluation of human female fertility by measuring effects on
What is already known about this subject
• At the time of launching biologics the effects on reproduction/lactation are unknown although many patients that receive these drugs are of reproductive age.
Because the effects are unknown, pregnancy during the use of these drugs is discouraged. It is expected that after launch pharmaceutical companies will actively update the results of pregnancy/lactation outcomes.
What this study adds
• Our study gives a perspective on the pre-and postauthorisation data on pregnancy/lactation provided for different biologics at the same indication range. It shows the differences between regulatory and clinical approaches to this issue. It also creates a paradigm for future studies of optimizing regulations regarding (contra) indication of biologics during pregnancy/lactation. b. In the post-marketing period adequacy is considered as reflecting information from spontaneous reports and publications in the literature on exposed pregnancy outcomes in the most up to date SmPC, additional to the data delivered in the initial dossier. 4 Retrospective data are considered as supportive information but not adequate.
Congenital malformations in the human fetus:
a. When during the pre-marketing period the results of unplanned pregnancies are specifically mentioned regarding congenital malformations.
b. When during the post-marketing period at least 300 pregnancies exposed during the first trimester are prospectively studied and a clear description of the incidences and type of congenital malformations is given. The number of 300 patients is necessary to be able to exclude the ≥10-fold risk of major congenital malformations compared to the general population. 5 In addition, when the assessment of fetal and/or neonatal toxicity for second/third trimester or pre-partum exposures are provided based on available prospective or retrospective data, this is also considered in this section as supportive information but not adequate. 28 When supportive information is only delivered by marketing authorization holders (MAHs), this is shown in red in Tables 2 and   3 . Orange colour in Tables 2 and 3 is considered as a symbol of being for a short time (< 5 years) in the market, adequacy of data for clinical management based on mentioned specific definitions, wouldn't apply in these cases for post-marketing period.
| Lactation information sections
Regarding lactation the data was divided into three categories for each biological: pre-clinical/animal studies, excretion in human breast milk and absorption in children.
Data were considered adequate for clinical management when they fulfilled the following criteria (shown in green in Tables 2 and 3) , stratified according to section:
1. Pre-clinical and/or animal studies: When the amounts and timing of drug concentration in the mother's milk of studied animals are provided. 45 As larger molecules such as immunoglobulins have more chance of being secreted into the milk due to larger gaps in breast alveolar cells during the first postpartum days, the timing of sampling is crucial for adequacy of information in this regard. 46 The statement of being detectable/undetectable in mother's milk in animals without exact amounts of excretion or the below the limit of quantitation (BLQ) levels is considered as supportive information but not adequate (transparency issue). Green: adequate data for clinical management; red: inadequate data for clinical management; orange: in the market for a short time (< 5 years), adequacy of data for clinical management was considered based on a specific definition, which is discussed in Material and Methods wouldn't apply in these cases.
Excretion in human breast
∞For rituximab, animal studies on pregnancy were done in cynomolgus monkeys, during the post-marketing period. *Pre: Pre-marketing period, **Post: Post-marketing period. The results for initial data based on the definitions of adequacy criteria in each section are shown in [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Post-marketing period: No prospective studies were performed to investigate congenital malformations in pregnancies exposed to abatacept, anakinra, belimumab, canakinumab, golimumab, rituximab, secukinumab, tocilizumab, ustekinumab and vedolizumab during the post-marketing period, and spontaneous reporting was relied on instead. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] Adalimumab, certolizumab pegol and etanercept initiated registries regarding pregnancy-related outcomes and congenital abnormality risk anticipation during the post-marketing period.
For infliximab one controlled observational study was conducted during the post-marketing period. The results of these studies are briefly mentioned in the latest SmPCs (see the Appendix). 36, 38, 39, 43 These biologics scored as delivering adequate data for clinical management in this section. Recommendations have changed in the most updated SmPCs based on these studies ( Table 1) .
The results for initial data regarding investigated three categories in lactation is shown in Table 3 . Based on the definitions of adequate for clinical management in each section, each investigated biological was scored as bellow (for detailed comparison please see Supporting Information Table S3A in the Appendix):
2. Lactation data a. Pre-clinical and/or animal studies:
The results of drug concentration in breast milk in preclinical/animal studies during the pre-marketing period were provided for following biologicals:
• Abatacept: In lactating rats, the milk-to-serum ratios for abatacept were 0.08-0.09. Abatacept was also detected in pup sera but the origin of this activity is unclear (from maternal milk or from maternal circulation). The lower limit of quantification (LLQ) for abatacept in rat milk was • Vedolizumab: Low levels (<300 mcg/L) on day 28 postpartum in breast milk in 3/11 animals at dosage of 100 mg/kg. Not detected in the breast milk at 10 mg/kg. 16 Timing of sample acquisition was only mentioned for ixekizumab and vedolizumab, therefore based on mentioned criteria these biologicals scored as adequate for preclinical/animal studies delivery criteria. No animal studies were performed to measure drug secretion into mother's milk in initial trials of adalimumab, anakinra, canakinumab, etanercept, infliximab, rituximab, sarilumab, secukinumab and tocilizumab, therefore data for these biologicals scored as not adequate for initial data on pre-clinical/animal studies. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] During the post-marketing period drug concentrations in mother's milk in animal studies were provided for etanercept (excreted in rat milk and in the serum of pips, the exact amounts and timing of detected drug are not provided) and rituximab (detectable in milk from lactating monkeys, the exact amounts and timing of detected drug are not provided).
For adalimumab, anakinra, canakinumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, there are no data available in this regard. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] b. Excretion in human breast milk:
Pre-marketing period: The concentration of the active substance/metabolites in human milk was not determined for any of the investigated biologicals before marketing authorization. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Post-marketing period: The concentration of the active substance/metabolites in human milk was estimated for adalimumab (a literature review by the manufacturer indicated low excretion of adalimumab in breast milk) and certolizumab pegol (minimal transfer to breast milk in 17 lactating women) during the post-marketing period. None of other investigated biologicals delivered data in this regard during the post-marketing period. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] c. Absorption in children:
Pre-marketing period: The estimated amount of medicinal product received by infants via milk was not calculated for any of the investigated biologicals before marketing authorization. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Post-marketing period: The amount of medicinal product received by infants via milk was estimated for certolizumab pegol (0.04-0.30%) and adalimumab (0.1-1%) based on the infant dose as a percentage of the weight-adjusted maternal dose. In both these amounts were <10% and therefore no additional studies were required based on mentioned criteria (see Materials and Methods). No other investigated biologicals delivered data in this regard during the post-marketing period. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] All together, initial data could not be scored as adequate 
| Suggestions for future legalisation procedures
In view of the current non-optimal situation, we suggest the following:
4.2 | Pre-clinical investigations: MAHs and regulatory authorities should reflect all the available data about pregnancy and lactation that is clearly related to the use of the biological in detail and numerically in SmPC and EPAR public assessment reports. Limiting the given information to conclusions and interpretations should be therefore avoided.
